Enlivex Therapeutics Ltd. ENLV
$ 1.25
5.81%
Annual report 2023
added 12-21-2024
Country |
Israel |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
CEO |
Dr. Shmuel Hess |
Employees in the company |
36 |
Shares |
18.6 M |
Market Cap[1] |
$ 23.2 M |
EBITDA (LTM) |
$ -10.1 M |
P/E (LTM) |
-5.45 |
P/S (LTM) |
- |
EPS (LTM) |
-0.73 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.